CAS 936623-90-4

Sacubitril-valsartan

Descrizione:

Sacubitril-valsartan è un farmaco combinato utilizzato principalmente nel trattamento dell'insufficienza cardiaca con frazione di eiezione ridotta. È composto da due componenti attivi: sacubitril, un inibitore della neprilisina che aumenta i livelli di peptidi natriuretici, e valsartan, un bloccante del recettore dell'angiotensina II (ARB) che aiuta a ridurre la pressione sanguigna e a diminuire lo sforzo sul cuore. Il meccanismo d'azione prevede l'inibizione duale del sistema renina-angiotensina-aldosterone (RAAS) e della via della neprilisina, portando a vasodilatazione, riduzione del volume sanguigno e miglioramento della gittata cardiaca. Sacubitril-valsartan viene tipicamente somministrato per via orale ed è noto per i suoi effetti favorevoli sulla morbilità e mortalità nei pazienti con insufficienza cardiaca. Gli effetti collaterali comuni possono includere ipotensione, iperkaliemia e compromissione renale. Il farmaco è controindicato nei pazienti con una storia di angioedema correlato a precedenti terapie con inibitori dell'ECA o ARB. In generale, Sacubitril-valsartan rappresenta un significativo progresso nella gestione dell'insufficienza cardiaca, offrendo un nuovo approccio terapeutico per migliorare i risultati dei pazienti.

Formula: (C₂₄H₂₉N₅O₃)·2(C₂₄H₂₉NO₅)·5(H₂O)·6Na

InChI: InChI=1S/C24H29N5O3.C24H29NO5.Na.H2O/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28);4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;1H2/t22-;17-,21+;;/m01../s1

InChI key: InChIKey=IFCNUAFRAJCYKN-DDXUJOENSA-N

SMILES: C([C@H](C[C@H](C(OCC)=O)C)NC(CCC(O)=O)=O)C1=CC=C(C=C1)C2=CC=CC=C2.C(N([C@@H]([C@H](C)C)C(O)=O)C(CCCC)=O)C1=CC=C(C2=C(C=CC=C2)C=3NN=NN3)C=C1.[Na].O

Sinonimi:

• <span class="text-smallcaps">L</span>-Valine, N-(1-oxopentyl)-N-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-, compd. with α-ethyl (αR,γS)-γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl[1,1′-biphenyl]-4-pentanoate, sodium salt, hydrate (2:2:6:5)
• Entresto
• L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, compd. with α-ethyl (αR,γS)-γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl[1,1'-biphenyl]-4-pentanoate, sodium salt, hydrate (2:2:6:5)
• Lcz 696
• Neparvis
• Sacubitril mixture with Valsartan
• Sacubitril-valsartan mixt.
• Sacubitril/Valsartan
• Valsartan-Sacubitril sodium
• Valsartan/Sacubitril 3Na-2.5 H2O
• trisodium 3-((1S,3R)-1-(biphenyl-4-ylmethyl)-3-(ethoxycarbonyl)butylcarbamoyl)propionate (S)-3-methyl-2-(pentanoyl-(2-(tetrazol-1-at-5-yl)biphenyl-4'-ylmethyl)amino)butyrate hemipentahydrate
• trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3-methyl-2-(pentanoyl{2''-(tetrazol-5-ylate)biphenyl-4-ylmethyl}amino)butyrate] hemipentahydrate
• LZC696
• (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)hexanamido)-3-methylbutanoic acid
• N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine, compd. with α-ethyl (αR,γS)-γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl[1,1'-biphenyl]-4-pentanoate, sodium salt, hydrate (2)
• LCZ696 interMediate
• LCZ696 Entresto
• [(C24H29N5O3).(C24H29NO5).2.5(H2O).3Na]
• 3-(1-Biphenyl-4-ylMethyl-3-ethoxycarbonyl-1-butylcarbaMoyl)propionate-3'-Methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylMethyl)aMino)butyrate
• Cocrystal of Sacubitril and Valsartan
• Valsartan-sacubitril(LCZ696)
• 4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate

Sodium (S)-2-(N-((2'-(2H-Tetrazol-5-Yl)-[1,1'-Biphenyl]-4-Yl)Methyl)Pentanamido)-3-Methylbutanoic Acid 4-(((2S,4R)-1-([1,1'-Biphenyl]-4-Yl)-5-Ethoxy-4-Methyl-5-Oxopentan-2-Yl)Amino)-4-Oxobutanoic Acid

CAS: 936623-90-4

Sodium (S)-2-(N-((2'-(2H-Tetrazol-5-Yl)-[1,1'-Biphenyl]-4-Yl)Methyl)Pentanamido)-3-Methylbutanoic Acid 4-(((2S,4R)-1-([1,1'-Biphenyl]-4-Yl)-5-Ethoxy-4-Methyl-5-Oxopentan-2-Yl)Amino)-4-Oxobutanoic Acid

Purezza: 98%

Peso molecolare: 1915.99g/mol

Ref: 54-OR1026669

Sacubitril/Valsartan

CAS: 936623-90-4

Sacubitril/Valsartan

Purezza: ≥98%

Peso molecolare: 957.99g/mol

Ref: 54-BUP16956

Sacubitril/Valsartan

CAS: 936623-90-4

Sacubitril/Valsartan (LCZ696) is an orally bioavailable, dual angiotensin II receptor and neprilysin inhibitor for treatment of hypertension and heart failure.

Formula: C₄₈H₅₅N₆O₈Na₃·5H₂O

Purezza: 99.75% - >99.99%

Colore e forma: Solid

Peso molecolare: 957.99

Ref: TM-T2318

Valsartan Sacubitril

CAS: 936623-90-4

Formula: C₂₄H₂₈NO₅C₂₄H₂₇N₅O₃Na(H₂₀)

Peso molecolare: 410.5 : 433.5 : 3(23.0) : 5/2(18.0)

Ref: ST-EA-CP-V3015

LCZ696

CAS: 936623-90-4

Lcz696 is an ester prodrug of the active compound crizotinib, which is a selective inhibitor of the enzyme tyrosine kinase. Lcz696 has been shown to be effective in combination therapy for the treatment of patients with metastatic non-small cell lung cancer and those who are resistant to first-line chemotherapy. This drug has also been shown to have beneficial effects on cardiac function and blood pressure. Lcz696 inhibits MMP-9 activity and reduces levels of natriuretic peptides, which may be due to its inhibition of Toll-like receptor 4 (TLR4).

Formula: C₂₄H₂₉N₅O₃•C₂₄H₂₉NO₅•(H₂O)₂•Na₃

Purezza: Min. 95%

Peso molecolare: 1,922.04 g/mol

Ref: 3D-FL137695